Treatment News : Egrifta Can Reduce Abdominal and Liver Fat in People With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 21, 2014

Egrifta Can Reduce Abdominal and Liver Fat in People With HIV

AIDS 2014The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV, MedPage Today reports. Researchers conducted a double-blind, randomized trial of 50 people who received either Egrifta (28 participants) or placebo (22 participants) for six months during 2013. They published their findings in The Journal of the American Medical Association and also presented them at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

Those taking Egrifta lowered their visceral adipose tissue by 34 square centimeters, compared with a 9 square cm drop among those taking the placebo. Lipid to water percentage, which is an indicator of liver fat, experienced a 2 percent median change in those taking the study drug, compared with a 0.9 percent median increase in the placebo group. Liver enzyme tests for indications of liver inflammation were lower among those taking Egrifta.

To read the MedPage Today story, click here.

To read the study abstract, click here.

Search: Egrifta, tesamorelin, abdominal fat, liver fat, HIV, 20th International AIDS Conference, AIDS 2014.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (4 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.